quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·44d
PRRelease
Edgewise Therapeutics Inc. logo

Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

EWTX· Edgewise Therapeutics Inc.
Health Care
Original source

Companies

  • EWTX
    Edgewise Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Sep 25UpdateGoldman$20.00
  • Jul 30UpdateRaymond James$46.00
  • Jun 30UpdateH.C. Wainwright$42.00
  • Apr 30UpdateGuggenheim$41.00
  • Apr 2UpdateScotiabank$14.00
  • Mar 7UpdateScotiabank$50.00

Related

  • SEC14h
    SEC Form DEFA14A filed by Edgewise Therapeutics Inc.
  • SEC14h
    SEC Form DEF 14A filed by Edgewise Therapeutics Inc.
  • INSIDER20d
    SEC Form 4 filed by Fox Jonathan C
  • INSIDER21d
    SEC Form 4 filed by Donovan Joanne M.
  • PR22d
    Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
  • INSIDER23d
    SEC Form 4 filed by Donovan Joanne M.
  • INSIDER24d
    SEC Form 4 filed by Donovan Joanne M.
  • SEC27d
    SEC Form 144 filed by Edgewise Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022